12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NP002: Phase I/II data

Top-line data from a double-blind, U.S. Phase I/II trial in 65 patients with levodopa-induced dyskinesias showed that NP002 plus levodopa was safe and well tolerated. Additionally, although the trial was not powered...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >